NeuroVive: large shareholder to participate in the rights issue
NeuroVive Pharmaceutical AB (publ) announces that Baulos Capital Belgium SA, one of the largest shareholders, intends to participate in the upcoming rights issue.Fredrik Olsson (Baulos Capital) has informed the NeuroVive board of Baulos Capital's intention to subscribe for shares in NeuroVive's rights issue with a subscription period between April 18 - May 2, 2016. The commitment means a subscription of at least 75,000 units to the rights issue subscription price of 42 SEK, corresponding to 3.15 MSEK. Baulos Capital has also agreed to sell off unexercised warrants outside of the stock